Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor

Posted on June 12, 2023

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the outcomes from a recent end-of-Phase 2 meeting with the U. S. Food and Drug Administration (FDA) regarding plans to advance ulixacaltamide into Phase 3 for essential tremor (ET).

6 thoughts on “Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor

  1. Is the Ulixacaltamide the same as PRAX-944 which has been mentioned before?

  2. Has frequent long term (2-3 months) HBOT therapy proven to be beneficial for people afflicted with ET (possibly due to neuroplasticity effects)?

    Have any reports of HBOT trials undertaken for relief of ET been made available?

    1. The IETF has not been involved in a study regarding the impact of HBOT therapy on ET so we can’t answer that. There have been studies done on its impact on brain injury (here is a link to that study: https://bmjopen.bmj.com/content/8/9/e023387). HBOT has traditionally be used to treat hypoxia-related conditions. There is a study that discusses therapeutic aspects of HBOT on neurologic conditions. Here is the link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564723/).

  3. Are there any further reports available on the efficacy of legal medicinal cannabis for the treatment of ET?

Comments are closed.